Verus Wealth Management LLC increased its holdings in the Vanguard S&P 500 Value ETF by 4.4%, adding 159 shares during the second quarter. The firm now holds 3,798 shares, according to its latest SEC filing. This move reflects an ongoing interest in value-oriented strategies among institutional investors.

Tepp RIA LLC reduced its Apple shares by 6.5% during the second quarter, selling 382 shares. Despite that decrease, the iPhone maker still accounts for 1.5% of the fund’s holdings, making it its ninth largest position.

Sowell Financial Services LLC recently cut its position in VICI Properties Inc. (NYSE:VICI) by 8.1%. According to a recent SEC filing, the firm sold 700 shares, leaving it with 7,931 shares in total.

Shira Ridge Wealth Management has slightly reduced its position in Apple, selling 281 shares to decrease its overall stake by 0.9%. Despite this move, the firm continues to hold nearly 30,000 shares of the tech giant, demonstrating its lingering confidence in Apple’s performance.

Capital Market Strategies LLC has reshaped its investment in Chevron, cutting its shares by 3.6% in the second quarter. The firm’s recent SEC filing sheds light on what prompted the decision.

Maple Capital Management Inc. has reduced its stake in Medtronic PLC by 5.2% during the first quarter, selling 165 shares in the process. The move leaves the institutional investor with 3,015 shares of the medical device giant, now valued at approximately $271,000.

Voleon Capital Management LP has substantially reduced its position in Carvana Co. According to a new SEC filing, the firm sold 21,315 shares, leaving it with 15,576 by the end of the first quarter.

Insight Holdings Group LLC has trimmed its stake in nCino Inc. by 1.2% in the first quarter, selling 54,876 shares. Despite the reduction, nCino still comprises about 9.5% of Insight Holdings’ portfolio, underscoring the fintech company’s continued significance.

Alyeska Investment Group L.P. has sold 8,907 shares of PROS Holdings, Inc., reflecting a 0.5% decrease in its overall position, according to a recent SEC filing. The investment firm continues to hold more than 1.7 million shares of the software maker.

ADAR1 Capital Management LLC has increased its stake in Inhibikase Therapeutics, Inc. by 0.4%, bringing its total holdings to over five million shares. The institutional investor’s move indicates growing confidence in the biotech firm, which now comprises about 2.1% of ADAR1’s portfolio.